1. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W754708
    Ouabagenin 508-52-1 98%
    Ouabagenin is a naturally occurring LXR ligand with LXR selective agonist activity. Ouabagenin acts as an EC 3.6.3.9 (Na(+)/K(+)- transport ATPase) inhibitor.
    Ouabagenin
  • HY-W766078
    1-beta-D-Arabinofuranosyluracil-13C,15N2 98%
    1-beta-D-Arabinofuranosyluracil-13C,15N2 (1-b-D-Arabinofuranosyluracil-13C,15N2; Uracil 1-β-D-arabinofuranoside-13C,15N2) is the 13C- and 15N-labeled labeled 1-beta-D-Arabinofuranosyluracil (HY-N6652). 1-beta-D-Arabinofuranosyluracil (Uracil 1-β-D-arabinofuranoside) isolated from the Caribbean sponge Tectitethya crypta, is a methoxyadenosine derivative. 1-beta-D-Arabinofuranosyluracil has demonstrated a diverse bioactivity profile including anti-inflammatory activity, analgesic and vasodilation properties. 1-beta-D-Arabinofuranosyluracil reduces a proliferation of mouse lymphoma cells.
    1-beta-D-Arabinofuranosyluracil-13C,15N2
  • HY-W767865
    Cyclic GMP sodium-13C5 98%
    Cyclic GMP sodium-13C5 is the 13C-labeled Cyclic GMP sodium (HY-113469A). Cyclic GMP (cGMP) sodium, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP sodium occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses.
    Cyclic GMP sodium-13C5
  • HY-W767936
    Moxonidine-13C,d3 98%
    Moxonidine-13C,d3 (BDF5895-13C,d3) is the 13C-labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an imidazoline type 1 receptor (I1-R) selective agonist and antihypertensive agent.
    Moxonidine-13C,d3
  • HY-W768333
    D-Ribofuranose-13C5
    D-Ribofuranose-13C5 (D-Ribose-13C5) is the 13C-labeled D-Ribofuranose (HY-113375). D-Ribofuranose (D-Ribose) is an endogenous metabolite present in Cerebrospinal_Fluid that can be used for the research of Ribose 5 Phosphate Isomerase Deficiency and Medium Chain Acyl Co A Dehydrogenase Deficiency.
    D-Ribofuranose-13C5
  • HY-W777002
    Famotidine-13C3 1185241-48-8 98%
    Famotidine-13C3 (MK-208-13C3) is the 13C-labeled Famotidine (HY-B0377). Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
    Famotidine-13C3
  • HY-W777156
    Carazolol-d6 hydrochloride 1184973-07-6 98%
    Carazolol-d6 (hydrochloride) is deuterium labeled Carazolol hydrochloride (HY-W517264). Carazolol hydrochloride is a highly potent antagonist of β12 adrenoceptor. Carazolol hydrochloride is also a potent, selective β3-adrenoceptor agonist. Carazolol hydrochloride can be used in the research of hypertension.
    Carazolol-d6 hydrochloride
  • HY-W777365
    Ethylenediaminetetraacetic acid-13C4 1215408-17-5 98%
    Ethylenediaminetetraacetic acid-13C4 (EDTA-13C4) is the 13C-labeled Ethylenediaminetetraacetic acid (HY-Y0682). Ethylenediaminetetraacetic acid (EDTA) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research.
    Ethylenediaminetetraacetic acid-13C4
  • HY-W777503
    Calindol hydrochloride-13C,D2 1217828-76-6 98%
    Calindol hydrochloride-13C,d2 is the deuterium and 13C labeled Calindol hydrochloride (HY-122819). Calindol hydrochloride is a positive allosteric modulator (PAM) of calcimimetic calcium-sensing receptor (CaSR) with an EC50 of 132 nM.
    Calindol hydrochloride-13C,D2
  • HY-W780166
    Uric acid-13C 139290-36-1 98%
    Uric acid-13C is the 13C-labeled Uric acid (HY-B2130). Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation.
    Uric acid-13C
  • HY-W782193
    Sulcatone-d5 55320-91-7 98%
    Sulcatone-d5 (6-Methyl-5-hepten-2-one-d5) is the deuterium labeled Sulcatone (HY-W010435). Sulcatone (6-Methyl-5-hepten-2-one) is a plant-derived volatile organic compound with activities such as insecticidal, antifungal, and blood pressure-lowering effects. Sulcatone also serves as an insect pheromone and an endogenous metabolite, which can be found in feces. Changes in Sulcatone levels can be used for the auxiliary diagnosis of ulcerative colitis.
    Sulcatone-d5
  • HY-W782550
    FK-352 143881-08-7 98%
    FK-352 is a selective adenosine A1 receptor antagonist. FK-352 significantly improves intradialytic hypotension in chronic hemodialysis. FK-352 can be used for the study of intradialytic hypotension.
    FK-352
  • HY-W783254
    C18 LPA 799279-67-7 98%
    C18 LPA (PA(18:0e/0:0)) is a water-soluble phospholipid that functions as a signaling molecule, influencing various cellular responses through G protein-coupled receptors (GPCRs). It is known to promote smooth muscle contraction, cytoskeletal rearrangement, and chemotaxis, while also playing a role in neurotransmitter release, cell proliferation, platelet aggregation, and Ca2+ mobilization. Elevated levels of C18 LPA in human plasma are associated with ovarian cancer and atherosclerosis, suggesting its potential as a biomarker for ovarian cancer.
    C18 LPA
  • HY-W854549
    Heparin pentasaccharide 104993-28-4 98%
    Heparin pentasaccharide (Fondaparinux) is a chemically synthesized selective factor Xa inhibitor with anticoagulant activity. Heparin pentasaccharide can be utilized in researches related to venous thromboembolic events.
    Heparin pentasaccharide
  • HY-W879307
    CP-201 2460280-41-3 98%
    CP-201 is a 1,4-naphthoquinone derivative with antiplatelet and antithrombotic activities. CP-201 shows concentration-dependent inhibitory effects on platelet aggregation induced by collagen and thrombin, with IC50 values of 4.1 and 4.6 μM, respectively. CP-201 displays a potent protective effect on pulmonary thrombosis in mice. CP-201 can be used for antithrombotic research.
    CP-201
  • HY-W923483
    C16-18:1 PC 95403-34-2 98%
    C16-18:1 PC (1-O-Hexadecyl-2-oleoyl-sn-glycero-3-phosphocholine), also known as 1-O-hexadecyl-2-oleoyl-sn-glycero-3-phosphocholine (HOPC), is a member of the platelet-activating factor (PAF) family of glycerophospholipids and serves as a pro-inflammatory lipid mediator with diverse biological and pharmacological effects; it features a mono-ether structure with an oleoyl chain (18:1) ester-linked at the sn-2 position and a hexadecyl chain (16:0) ether-linked at the sn-1 position.
    C16-18:1 PC
  • HY-W990281
    B-GYKI-38233 hydrochloride 100751-82-4
    B-GYKI-38233 hydrochloride (Restacorin) is a sodium channel blocker used in antiarrhythmic research.
    B-GYKI-38233 hydrochloride
  • HY-W996116
    AZM198 1933460-23-1
    AZM198 is a selective, orally active, and irreversible MPO inhibitor with an IC50 of 15.0 nM. AZM198 has an IC50 of 19 μM for CYP3A4. AZM198 has favorable lipophilicity, membrane permeability, metabolic stability, safety, and pharmacokinetic properties. AZM198 exhibits activity in improving vascular function, atherosclerotic plaques, pulmonary hypertension, kidney disease, visceral inflammatory fat deposition, ectopic fat deposition, and hepatic fibrosis.
    AZM198
  • HY-Y0366S4
    Lauric acid-13C-1 287100-78-1 98%
    Lauric acid-13C-1 is the deuterium labeled Lauric acid. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
    Lauric acid-13C-1
  • HY-Y0682AR
    Ethylenediaminetetraacetic acid disodium dihydrate (Standard) 6381-92-6
    Ethylenediaminetetraacetic acid (disodium dihydrate) (Standard) is the analytical standard of Ethylenediaminetetraacetic acid (disodium dihydrate). This product is intended for research and analytical applications. Ethylenediaminetetraacetic acid (EDTA) disodium dehydrate is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid disodium dehydrate has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid disodium dehydrate decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid disodium dehydrate can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid disodium dehydrate can be used for coronary artery disease and neural system disease research[4].
    Ethylenediaminetetraacetic acid disodium dihydrate (Standard)
Cat. No. Product Name / Synonyms Application Reactivity